Aricept 23 mg/Aricept Evess

Aricept 23 mg/Aricept Evess

donepezil

Manufacturer:

Eisai

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Donepezil HCl
Indications/Uses
Symptomatic treatment of mild to moderate & severe Alzheimer's dementia (for Aricept 23 mg, in patients whose condition is not adequately controlled by donepezil HCl 10 mg).
Dosage/Direction for Use
Aricept 23 mg Adult/elderly 23 mg once daily. Aricept Evess Adult/elderly Initially 5 mg once daily at bedtime, maintain for at least 1 mth. May be increased to 10 mg once daily, following 4-6 wk clinical assessment. If not adequately controlled, may be increased to 23 mg (one Aricept 23-mg FC tab).
Administration
May be taken with or without food. Take at bedtime. FC tab: Swallow whole, do not split/crush. orodispersible tab: Place tab on the tongue & allow to dissolve; it can then be swallowed w/ water.
Contraindications
Hypersensitivity to donepezil HCl or piperidine derivatives. Pregnancy & lactation.
Special Precautions
Exaggerated succinylcholine-type muscle relaxation during anaesth. Vagotonic effects on SA & AV nodes; syncopal episodes. May cause diarrhea, nausea, vomiting, wt loss. Patients w/ increased risk for developing ulcers eg, history of ulcer disease & those receiving concurrent NSAIDs. May cause bladder outflow obstruction. May exacerbate or induce extrapyramidal symptoms. History of asthma or obstructive pulmonary disease. Avoid concomitant use w/ other inhibitors of acetylcholinesterase, cholinergic system agonists or antagonists. Discontinue therapy if signs & symptoms of neuroleptic malignant syndrome or presents w/ unexplained high fever develop. Patients w/ predisposing/risk factors eg, prior history of muscular disorders, uncontrolled hypothyroidism, hepatic or renal impairment. Concomitant use w/ rhabdomyolysis-causing medications (eg, statins, antipsychotics, SSRIs/SNRIs). Dementia may affect ability to drive or operate machinery. Not recommended for childn. Aricept 23 mg Patients weighing <55 kg are more prone to nausea, vomiting & decrease in wt than those weighing ≥55 kg.
Adverse Reactions
Common cold; anorexia; hallucinations, agitation, aggressive behaviour; syncope, dizziness, insomnia; diarrhoea, vomiting, nausea, abdominal disturbance; rash, pruritus; muscle cramps; urinary incontinence; headache, fatigue, pain; accident.
Drug Interactions
Metabolism may be inhibited w/ ketoconazole & quinidine, CYP450, 3A4 & 2D6 inhibitors. Reduced clearance w/ CYP2D6 inhibitor. Increased rate of elimination w/ CYP2D6 & CYP3A4 inducers (eg, phenytoin carbamazepine, dexamethasone, rifampin & phenobarb). May interfere w/ the activity of anticholinergics. Synergistic effect w/ succinylcholine, similar neuromuscular blocking agents or cholinergic agonists (eg, bethanechol).
MIMS Class
Neurodegenerative Disease Drugs
ATC Classification
N06DA02 - donepezil ; Belongs to the class of anticholinesterases. Used in the management of dementia.
Presentation/Packing
Form
Aricept 23 mg FC tab 23 mg
Packing/Price
28's
Form
Aricept Evess orodispersible tab 10 mg
Packing/Price
28's
Form
Aricept Evess orodispersible tab 5 mg
Packing/Price
28's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in